Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according to results of a Phase I clinical trial presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, held April 17-22.
Please follow and like us:
